{"count": 9, "results": [{"_id": "32654569", "pmid": 32654569, "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-beta signaling.", "journal": "Biotech Histochem", "authors": ["Liu X", "Sun Z", "Wang H"], "date": "2021-02-01T00:00:00Z", "doi": "10.1080/10520295.2020.1776896", "meta_date_publication": "2021 Feb", "meta_volume": "96", "meta_issue": "2", "meta_pages": "146-152", "score": 50249.98, "text_hl": "We found that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment decreased @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colon mucosal damage@@@ and preserved intestinal transit. ", "citations": {"NLM": "Liu X, Sun Z, Wang H. Metformin alleviates experimental colitis in mice by up-regulating TGF-beta signaling. Biotech Histochem. 2021 Feb;96(2):146-152. PMID: 32654569", "BibTeX": "@article{32654569, title={Metformin alleviates experimental colitis in mice by up-regulating TGF-beta signaling.}, author={Liu X and Sun Z and Wang H}, journal={Biotech Histochem}, volume={96}, number={2}, pages={146-152}}"}}, {"_id": "34749618", "pmid": 34749618, "title": "The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer.", "journal": "Curr Diabetes Rev", "authors": ["Ala M"], "date": "2022-01-01T00:00:00Z", "doi": "10.2174/1573399818666211105125129", "meta_date_publication": "2022", "meta_volume": "18", "meta_issue": "8", "meta_pages": "e051121197762", "score": 50244.17, "text_hl": "Interestingly, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ decreases the incidence of @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colonic adenoma@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Acromegaly @DISEASE_MESH:D000172 @@@acromegaly@@@ and reduces the incidence of @DISEASE_Inflammatory_Bowel_Diseases @DISEASE_MESH:D015212 @@@inflammatory bowel disease@@@ (@DISEASE_Inflammatory_Bowel_Diseases @DISEASE_MESH:D015212 @@@IBD@@@) among @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@, which can indirectly lower the risk of @DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@CRC@@@. ", "citations": {"NLM": "Ala M. The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. Curr Diabetes Rev. 2022;18(8):e051121197762. PMID: 34749618", "BibTeX": "@article{34749618, title={The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer.}, author={Ala M}, journal={Curr Diabetes Rev}, volume={18}, number={8}, pages={e051121197762}}"}}, {"_id": "38518387", "pmid": 38518387, "title": "Metformin's role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study.", "journal": "Cancer Epidemiol", "authors": ["Lawler T", "Walts ZL", "Giurini L", "Steinwandel M", "Lipworth L", "Murff HJ", "Zheng W", "Warren Andersen S"], "date": "2024-03-21T00:00:00Z", "doi": "10.1016/j.canep.2024.102566", "meta_date_publication": "2024 Mar 21", "meta_volume": "90", "meta_issue": "", "meta_pages": "102566", "score": 50242.85, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ use was associated with a significantly lower @DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@CRC@@@ risk (HR [95% CI]: 0.71 [0.55-0.93]), with consistent results for both @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colon@@@ (0.80 [0.59-1.07]) and @DISEASE_Rectal_Neoplasms @DISEASE_MESH:D012004 @@@rectal cancers@@@ (0.49 [0.28-0.86]). ", "citations": {"NLM": "Lawler T, Walts ZL, Giurini L, Steinwandel M, Lipworth L, Murff HJ, Zheng W, Warren Andersen S. Metformin's role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study. Cancer Epidemiol. 2024 Mar 21;90():102566. PMID: 38518387", "BibTeX": "@article{38518387, title={Metformin's role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study.}, author={Lawler T and Walts ZL and Giurini L and Steinwandel M and Lipworth L and Murff HJ and Zheng W and Warren Andersen S}, journal={Cancer Epidemiol}, volume={90}, pages={102566}}"}}, {"_id": "39602956", "pmid": 39602956, "title": "Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4/MyD88/NFkappaB/MAPK pathway and macrophage M2 polarization.", "journal": "Int Immunopharmacol", "authors": ["Lai X", "Liu B", "Wan Y", "Zhou P", "Li W", "Hu W", "Gong W"], "date": "2024-11-26T00:00:00Z", "doi": "10.1016/j.intimp.2024.113683", "meta_date_publication": "2024 Nov 26", "meta_volume": "144", "meta_issue": "", "meta_pages": "113683", "score": 50241.516, "text_hl": "RESULTS: Our results showed that low- or high-dose @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ ameliorates @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colonic mucosal damage@@@, reduces @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@colonic inflammation@@@, and eventually inhibits @DISEASE_Carcinogenesis @DISEASE_MESH:D063646 @@@colorectal tumorigenesis@@@ in the ETBF/@CHEMICAL_Azoxymethane @CHEMICAL_MESH:D001397 @@@AOM@@@/@CHEMICAL_Dextran_Sulfate @CHEMICAL_MESH:D016264 @@@DSS@@@ @SPECIES_10090 @@@mouse@@@ model. ", "citations": {"NLM": "Lai X, Liu B, Wan Y, Zhou P, Li W, Hu W, Gong W. Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4/MyD88/NFkappaB/MAPK pathway and macrophage M2 polarization. Int Immunopharmacol. 2024 Nov 26;144():113683. PMID: 39602956", "BibTeX": "@article{39602956, title={Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4/MyD88/NFkappaB/MAPK pathway and macrophage M2 polarization.}, author={Lai X and Liu B and Wan Y and Zhou P and Li W and Hu W and Gong W}, journal={Int Immunopharmacol}, volume={144}, pages={113683}}"}}, {"_id": "35724510", "pmid": 35724510, "title": "Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis.", "journal": "Biomed Pharmacother", "authors": ["Shaaban AA", "Abdelhamid AM", "Shaker ME", "Cavalu S", "Maghiar AM", "Alsayegh AA", "Babalghith AO", "El-Ahwany E", "Amin NA", "Mohammed OA", "Eissa H", "Gaafar AGA", "Batiha GE", "Saber S"], "date": "2022-09-01T00:00:00Z", "doi": "10.1016/j.biopha.2022.113247", "meta_date_publication": "2022 Sep", "meta_volume": "153", "meta_issue": "", "meta_pages": "113247", "score": 50239.44, "text_hl": "As a result, such dynamic synergy was efficient in combating @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colon damage@@@ and immune-cell infiltration. ", "citations": {"NLM": "Shaaban AA, Abdelhamid AM, Shaker ME, Cavalu S, Maghiar AM, Alsayegh AA, Babalghith AO, El-Ahwany E, Amin NA, Mohammed OA, Eissa H, Gaafar AGA, Batiha GE, Saber S. Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis. Biomed Pharmacother. 2022 Sep;153():113247. PMID: 35724510", "BibTeX": "@article{35724510, title={Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: A new management paradigm for ulcerative colitis.}, author={Shaaban AA and Abdelhamid AM and Shaker ME and Cavalu S and Maghiar AM and Alsayegh AA and Babalghith AO and El-Ahwany E and Amin NA and Mohammed OA and Eissa H and Gaafar AGA and Batiha GE and Saber S}, journal={Biomed Pharmacother}, volume={153}, pages={113247}}"}}, {"_id": "27256336", "pmid": 27256336, "title": "Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II.", "journal": "J Gastrointest Cancer", "authors": ["Jain D", "Chhoda A", "Uribe J"], "date": "2016-12-01T00:00:00Z", "doi": "10.1007/s12029-016-9842-4", "meta_date_publication": "2016 Dec", "meta_volume": "47", "meta_issue": "4", "meta_pages": "404-408", "score": 50057.78, "text_hl": "Effect of @GENE_INS @GENE_3630 @@@Insulin@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Combination Treatment on @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@Colon Adenoma@@@ and Advanced @DISEASE_Adenoma @DISEASE_MESH:D000236 @@@Adenoma@@@ Among @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@DM II@@@.", "citations": {"NLM": "Jain D, Chhoda A, Uribe J. Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II. J Gastrointest Cancer. 2016 Dec;47(4):404-408. PMID: 27256336", "BibTeX": "@article{27256336, title={Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II.}, author={Jain D and Chhoda A and Uribe J}, journal={J Gastrointest Cancer}, volume={47}, number={4}, pages={404-408}}"}}, {"_id": "23621234", "pmid": 23621234, "title": "Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells.", "journal": "Asian Pac J Cancer Prev", "authors": ["Avci CB", "Harman E", "Dodurga Y", "Susluer SY", "Gunduz C"], "date": "2013-01-01T00:00:00Z", "doi": "10.7314/apjcp.2013.14.2.765", "meta_date_publication": "2013", "meta_volume": "14", "meta_issue": "2", "meta_pages": "765-8", "score": 50045.453, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ inhibits the proliferation of a range of @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancer@@@ cells including @DISEASE_Prostatitis @DISEASE_MESH:D011472 @@@prostate@@@, @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colon@@@, @DISEASE_Ovarian_Neoplasms @DISEASE_MESH:D010051 @@@breast, ovarian@@@, and @DISEASE_Glioma @DISEASE_MESH:D005910 @@@glioma@@@ lines. ", "citations": {"NLM": "Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14(2):765-8. PMID: 23621234", "BibTeX": "@article{23621234, title={Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells.}, author={Avci CB and Harman E and Dodurga Y and Susluer SY and Gunduz C}, journal={Asian Pac J Cancer Prev}, volume={14}, number={2}, pages={765-8}}"}}, {"_id": "28821163", "pmid": 28821163, "title": "Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling.", "journal": "Biomed Pharmacother", "authors": ["Pandey A", "Verma S", "Kumar VL"], "date": "2017-10-01T00:00:00Z", "doi": "10.1016/j.biopha.2017.08.020", "meta_date_publication": "2017 Oct", "meta_volume": "94", "meta_issue": "", "meta_pages": "1121-1128", "score": 50044.695, "text_hl": "The results of this study show that treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ significantly decreased @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colonic mucosal damage@@@, maintained oxidative homeostasis and normalized intestinal transit and W/L ratio in a dose-dependent manner. ", "citations": {"NLM": "Pandey A, Verma S, Kumar VL. Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling. Biomed Pharmacother. 2017 Oct;94():1121-1128. PMID: 28821163", "BibTeX": "@article{28821163, title={Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling.}, author={Pandey A and Verma S and Kumar VL}, journal={Biomed Pharmacother}, volume={94}, pages={1121-1128}}"}}, {"_id": "30514262", "pmid": 30514262, "pmcid": "PMC6280542", "title": "The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients", "journal": "BMC Cancer", "authors": ["Petrera M", "Paleari L", "Clavarezza M", "Puntoni M", "Caviglia S", "Briata IM", "Oppezzi M", "Mislej EM", "Stabuc B", "Gnant M", "Bachleitner-Hofmann T", "Roth W", "Scherer D", "Haefeli WE", "Ulrich CM", "DeCensi A"], "date": "2018-12-04T00:00:00Z", "doi": "10.1186/s12885-018-5126-7", "meta_date_publication": "2018 Dec 4", "meta_volume": "18", "meta_issue": "1", "meta_pages": "1210", "score": 50038.203, "text_hl": "Epidemiological studies and cardiovascular prevention trials have shown that low-dose @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@ can reduce @DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@colorectal cancer@@@ (@DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@CRC@@@) incidence and mortality, including inhibition of distant @DISEASE_Neoplasm_Metastasis @DISEASE_MESH:D009362 @@@metastases@@@. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has also been associated with decreased @<m>DISEASE_Colonic_Diseases</m> @DISEASE_MESH:D003108 @@@colon adenoma@@@ recurrence in clinical trials and lower @DISEASE_Colorectal_Neoplasms @DISEASE_MESH:D015179 @@@CRC@@@ incidence and mortality in epidemiological studies in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetics@@@. ", "citations": {"NLM": "Petrera M, Paleari L, Clavarezza M, Puntoni M, Caviglia S, Briata IM, Oppezzi M, Mislej EM, Stabuc B, Gnant M, Bachleitner-Hofmann T, Roth W, Scherer D, Haefeli WE, Ulrich CM, DeCensi A. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients BMC Cancer. 2018 Dec 4;18(1):1210. PMID: 30514262", "BibTeX": "@article{30514262, title={The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 x 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients}, author={Petrera M and Paleari L and Clavarezza M and Puntoni M and Caviglia S and Briata IM and Oppezzi M and Mislej EM and Stabuc B and Gnant M and Bachleitner-Hofmann T and Roth W and Scherer D and Haefeli WE and Ulrich CM and DeCensi A}, journal={BMC Cancer}, volume={18}, number={1}, pages={1210}}"}}]}